Kenneth Cusi
Kenneth Cusi is an expert in Endocrinology at University of Florida (United States). As of October 2026, ScienceLeadR ranks Kenneth Cusi in the top 1% of experts worldwide for MASH, Insulin Resistance and Hyperinsulinism. Kenneth Cusi has authored 379 publications, the most recent in 2026, and is an investigator in 22 clinical trials, 2 of them ongoing. SLR score: 1,979 (community average: 125). How the SLR is computed.
LeadR Profile
Endocrinology
Subspecialties: Hepatology - Gastroenterology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1995 - 2026
Number : 379
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Prediabetes and diabetes as drivers of fibrosis in MASLD: roles of obesity, adipose tissue dysfunction and insulin resistance. PMID 42926238 — diabetes mellitus, endocrinology, insulin resistance, insulin, fibrosis, elasticity imaging techniques, liver, prediabetic state, prevalence, obesity, risk factors, tissues, adipose tissue, diabetes mellitus, type 2 | Diabetologia | 2026 | 0 |
| Liver Fat Changes in Patients With Type 2 Diabetes by Presence of Genetic Hepatic Steatosis: A Post Hoc Analysis of SURPASS-3 MRI. PMID 42576670 — liver diseases, diabetes mellitus, insulin, magnetic resonance imaging, liver, alleles, genotype, fatty liver, polymorphism, single nucleotide, diabetes mellitus, type 2 | Liver Int | 2026 | 0 |
| Is MASLD an independent risk factor for micro- and macrovascular complications of diabetes? A critical reappraisal and future directions. PMID 42542457 — liver diseases, diabetes mellitus, non-alcoholic fatty liver disease, liver, risk factors, diabetes complications, diabetes mellitus, type 2 | Diabetologia | 2026 | 2 |
| Closing the Implementation Gap: New Models of Care to End Chronic Liver Disease. PMID 42266907 — liver diseases, liver | Lancet Reg Health Eur | 2026 | 0 |
| High Prevalence of Metabolic Dysfunction-Associated Steatohepatitis With Significant Fibrosis in Primary Care and Endocrinology Clinics. PMID 42056678 — endocrinology, insulin resistance, insulin, fibrosis, non-alcoholic fatty liver disease, liver, prevalence, obesity, outpatients, diabetes mellitus, type 2 | Diabetes Obes Metab | 2026 | 0 |
Clinical Studies 22
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 2
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction Associated Steatotic Liver Disease (SYNERGY Outcomes) NCT07165028 — liver diseases, non-alcoholic fatty liver disease, liver, alcoholics, incretins, fatty liver, fatty liver, alcoholic | Phase 3 | Recruiting | 2025 |
| Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT) NCT03460769 — diabetes mellitus, pancreatic neoplasms, pancreatitis, chronic, neoplasms, pancreatitis, data management, diagnosis, meals | N/A | Active not recruiting | 2021 |
LeadR Networks
Main global connection map